Chandelier
Senior Member (Voting Rights)

Nicotine patches help relieve symptoms in some people with Long COVID. Can the science behind it lead to future therapies? - The Sick Times
Some people with Long COVID and the providers who were treating them wondered if nicotine, delivered by a mechanism other than cigarettes, might help with the chronic disease. For the next several years, white papers used anecdotal evidence to expand on that initial hypothesis.

Short AI Summary:
Nicotine Patches as a Potential Treatment for Long COVID
Nicotine patches are gaining attention as an experimental approach to alleviate Long COVID symptoms. Though originally designed for smoking cessation, these patches have shown promise for some patients experiencing post-viral fatigue, cognitive issues, and sensory loss. Reports from online communities and patient-led initiatives highlight both positive outcomes and adverse reactions, prompting increased scientific interest.
Despite anecdotal success, the exact mechanisms remain unclear. While the early “spike protein displacement” theory offered a simple explanation, newer research suggests a more complex interaction between nicotine and neural receptors. Pharmacologists now believe nicotine’s impact on inflammation and the autonomic nervous system may play a more significant role.
Because Long COVID affects multiple systems, researchers face challenges identifying which subtypes might respond best to nicotine. Patient groups like the Nicotine Test have created detailed dosing protocols, starting with low doses and gradually increasing use. However, experts caution against high doses or alternative nicotine delivery methods, such as vaping.
Ongoing research aims to clarify nicotine’s role and possibly isolate its beneficial effects without associated risks. Until then, nicotine patches remain an off-label, patient-driven option — promising for some, but not without potential drawbacks.